Seelos Therapeutics Inc (NASDAQ:SEEL) shares shot up 5.6% during trading on Friday . The company traded as high as $1.53 and last traded at $1.52, 673,600 shares were traded during trading. An increase of 9% from the average session volume of 618,751 shares. The stock had previously closed at $1.44.

A number of brokerages have recently commented on SEEL. HC Wainwright raised their price target on Seelos Therapeutics from $2.00 to $4.00 and gave the company a “buy” rating in a report on Monday, November 18th. Benchmark initiated coverage on Seelos Therapeutics in a report on Thursday, November 14th. They set a “buy” rating and a $4.00 target price on the stock. Finally, Zacks Investment Research lowered Seelos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 23rd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $4.44.

The business has a fifty day moving average of $1.29 and a 200-day moving average of $1.30. The company has a current ratio of 2.93, a quick ratio of 2.93 and a debt-to-equity ratio of 0.03.

Seelos Therapeutics (NASDAQ:SEEL) last released its earnings results on Thursday, November 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The company had revenue of $0.38 million during the quarter. Analysts anticipate that Seelos Therapeutics Inc will post -3.63 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the stock. Sabby Management LLC acquired a new position in Seelos Therapeutics during the third quarter worth about $451,000. Virtu Financial LLC acquired a new position in Seelos Therapeutics during the third quarter worth about $68,000. Wedbush Securities Inc. grew its holdings in Seelos Therapeutics by 412.7% during the third quarter. Wedbush Securities Inc. now owns 82,028 shares of the company’s stock worth $75,000 after acquiring an additional 66,028 shares during the period. Uniplan Investment Counsel Inc. acquired a new position in Seelos Therapeutics during the second quarter worth about $1,516,000. Finally, Citadel Advisors LLC acquired a new position in Seelos Therapeutics during the second quarter worth about $29,000. 12.42% of the stock is currently owned by hedge funds and other institutional investors.

Seelos Therapeutics Company Profile (NASDAQ:SEEL)

Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients.

Recommended Story: What is a death cross?

Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.